For Melanoma, Pretreatment Influences Vemurafenib Therapy Outcomes
the Cancer Therapy Advisor take:
According to a new study published in the journal Annals of Oncology, researchers have found that the type of pretreatment, such as chemotherapy or immunotherapy, greatly influences vemurafenib therapy outcomes for patients with BRAF V600 mutated melanoma.
For the mutlicenter, retrospective study, researchers sought to investigate the patterns associated with vemurafenib therapy outcomes and to identify any predictive factors of therapy response. Researchers identified 300 patients with BRAF V600 mutated stage 4 melanoma from 14 institutions. Patients had a median follow-up time of 13 months, a median progression-free survival of 5.1 months, and a median overall survival of 7.6 months.
Results showed that patients with a serum LDH ≤ULN (P = 0.0000001), an ECOG overall performance status of 0 (P = 0.00089), and BRAF V600E mutated disease (P = 0.016) had the best response under vemurafenib therapy. In addition, previous immunotherapy was associated with a positive impact on survival (HR = 0.57; P = 0.025), while prior chemotherapy (HR = 2.17; P = 0.039) and tyrosine kinase inhibitor therapy (HR = 1.86; P = 0.014) were associated with a negative impact.
Furthermore, the researchers found that elevated serum LDH (HR = 1.45; P = 0.012), age >55 years (HR = 0.72; P = 0.019), and gender (HR = 0.70; P = 0.039) are independent predictors of vemurafenib therapy outcomes.
Type of pretreatment greatly influences vemurafenib therapy outcomes for BRAF V600 mutated melanoma.
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Arrival of CAR-T Immunotherapy Raise Hopes for Treatment and Anxieties About Costs
- St John's Wort and Cancer
- Osimertinib Granted Breakthrough Therapy Designation as First-line Treatment for EGFR-positive NSCLC
- Radiation Therapy Increases 5-year Rate of Cardiac Events in Small-cell Lung Cancer
- Pazopanib: Where Does It Stand as Adjuvant Therapy in Localized RCC?
- NSCLC: Researchers Identify Socioeconomic Factors Linked to Overall Survival
- Savolitinib Plus Gefitinib May Be Effective in EGFR-Mutant, MET-amplified NSCLC
- Maintenance Pazopanib Provides PFS, not OS, Benefit in Small-cell Lung Cancer
- Pembrolizumab Plus Pemetrexed, Carboplatin Prolongs Survival in NSCLC
- Repeat T790M Testing Recommended for TKI-resistant Patients With NSCLC